Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Bradley J. Monk(Florida Cancer Specialists & Research Institute), Robert Morris(Massachusetts General Hospital), Jesús García-Donás(Universidad San Pablo CEU), Peter G. Rose(Cleveland Clinic), Fatemeh Tavakkoli(AVEO Oncology (United States)), Rodabe N. Amaria(The University of Texas MD Anderson Cancer Center), Stéphanie Gaillard(Sidney Kimmel Cancer Center), Axel Walther, Brian M. Slomovitz(Mount Sinai Medical Center), Robert M. Wenham(Moffitt Cancer Center), Jacqueline M. Tromp, Emese Zsíros, Maria Fardis(Pharmacyclics (United States)), Andrew Artz, Sajeve Thomas(Orlando Health), Robert P. Edwards(Cancer Research UK Technology), Jason Chesney(University of Louisville Hospital), Huiling Li(Theravance Biopharma (United States)), Koji Matsuo(University of Southern California)
Cited by 142
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k